



2022年9月30日(金) 12:00

プログラム
配信開始予定

2023年3月31日まで掲載予定

日本の実臨床に即した視点で、ESMO Congress 2022の注目演題を解説する学会公式プログラム

DiscussionおよびQ&A動画(ご質問を受け付けます)も公開

JSMOがん薬物療法専門医の更新資格に必要な10単位を付与

※本コンテンツの閲覧には、登録によるアクセスキー発行(有料)が必須となります。お申し込み方法は以下をご覧ください。
 JSMO会員またはESMO会員の方:13,200円(税込) 非会員の方:33,000円(税込)

閲覧方法

① トップページ(<https://bestofesmo.jp/>)より
お申し込み・アクセスキー受領② トップページ(<https://bestofesmo.jp/>)より
アクセスキーにてログイン

トップページには
こちらの二次元
コードからもアク
セス可能です。



▼ 以下の先生方による、各領域6演題分の解説動画、DiscussionおよびQ&A動画がご視聴可能です。▼

解説領域と先生方のご紹介

Programme Chair	佐治 重衡 先生(福島県立医科大学)
肺がん	大熊 裕介 先生(司会: 国立がん研究センター中央病院) 赤松 弘朗 先生(解説: 和歌山県立医科大学) 谷崎 潤子 先生(解説: 近畿大学)
消化器がん	林 義人 先生(司会: 大阪大学大学院) 小野澤 祐輔 先生(司会: 静岡県立静岡がんセンター) 砂川 優 先生(解説: 聖マリアンナ医科大学) 大場 彬博 先生(解説: 国立がん研究センター中央病院)
婦人科がん	野村 基雄 先生(司会: 京都大学医学部附属病院) 原野 謙一 先生(解説: 国立がん研究センター東病院)
乳がん	小野 麻紀子 先生(司会: がん研究会有明病院) 原文 堅 先生(解説: がん研究会有明病院)
泌尿器がん	前嶋 愛子 先生(司会: 国立がん研究センター中央病院) 松原 伸晃 先生(解説: 国立がん研究センター東病院)

解説演題一覧

肺がん		解説：赤松 弘朗 先生 (和歌山県立医科大学 呼吸器内科・腫瘍内科) 谷崎 潤子 先生 (近畿大学医学部 内科学教室 腫瘍内科部門)
演題番号	演題	演者
LBA10	Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreak 200 phase III study	Melissa L. Johnson
LBA11	IPSOS: Results from a Phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen	Siow Ming Lee
LBA47	Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA	Masahiro Tsuboi
LBA52	Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study	Julien Mazieres
LBA59	Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)	Melissa L. Johnson
972O	Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial	Gerard Zalcman

消化器がん		解説：砂川 優 先生 (聖マリアンナ医科大学 臨床腫瘍学講座) 大場 彬博 先生 (国立がん研究センター中央病院 肝胆脾内科)
演題番号	演題	演者
LBA25	FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer	N. Arvind Dasari
LBA21	FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group	Marinde J. Bond
388P	Early tumor shrinkage (ETS) and depth of response (DpR) analyses in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): Results from the phase III PARADIGM trial	Kei Muro
LBA22	Phase III study with FOLFIRI/Cetuximab versus FOLFIRI/Cetuximab followed by Cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES Study	Armando Orlandi
LBA12	Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRI)-naïve cholangiocarcinoma (CCA): ReFocus trial	Antoine Hollebecque
LBA34	Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)	Richard S. Finn
LBA60	Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 – UCGI 36 – GEMPAX UNICANCER study	Christelle De la Fouchardiere

婦人科がん		解説：原野 謙一 先生 (国立がん研究センター東病院 先端医療科・腫瘍内科)
演題番号	演題	演者
LBA29	Final overall survival (OS) results from the Phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)	Isabelle L. Ray-Coquard
LBA30	Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)	Jean Emmanuel Kurtz
LBA31	Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial	Keiichi Fujiwara
LBA32	Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (Phase II): Safe and effective in both PD-L1 positive and negative	Sungjong Lee
517O	Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial	Paul DiSilvestro
525MO	Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775	Vicky Makker

乳がん		解説：原文 堅 先生 (がん研究会有明病院乳腺センター 乳腺内科)
演題番号	演題	演者
LBA13	Nivolumab and ipilimumab in early stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial	Marleen Kok
LBA14	Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTCycle trials	Oleg Gluz
LBA15	MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)	Matthew P. Goetz
LBA72	Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial	Maria Fernanda Mosele
LBA76	Overall survival (OS) results from the phase III TROPICS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)	Hope S. Rugo
211MO	Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2- locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study	Miguel Martin Jimenez

泌尿器がん		解説：松原 伸晃 先生 (国立がん研究センター東病院 腫瘍内科)
演題番号	演題	演者
LBA4	Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial	Robert J. Motzer
LBA62	Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol	Gerhardt Attard
LBA66	IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection	Axel Bex
LBA73	Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)	Jonathan E. Rosenberg
LBA8	Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)	Toni K. Choueiri
1357O	Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)	Fred Saad

※解説演題は変更になることがありますので、予めご了承ください。